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Noninferiority trials
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Merck Research Laboratories, West Point, Pennsylvania, USA
Abstract
Noninferiority trials are intended to show that the effect of a new treatment is not worse than
that of an active control by more than a specified margin. These trials have a number of
inherent weaknesses that superiority trials do not: no internal demonstration of assay
sensitivity, no single conservative analysis approach, lack of protection from bias by blinding,
and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be
necessary when a placebo group can not be ethically included, but it should be recognized
that the results of such trials are not as credible as those from a superiority trial.
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Introduction
In one of the biggest dilemmas facing cardiovascular clinical
research, clinical trials are increasingly being required to
show benefits on clinical end-points rather than surrogate
end-points, while at the same time the incremental benefits
of newer treatments are getting smaller. These two factors
have a huge impact on sample size, which has led some
investigators to design trials to show that the new treatment
has an effect similar to that of the standard, rather than out-
right superiority. Recent examples of fibrinolytic trials that
have demonstrated similar effects of two drugs are
ASSENT (Assessment of the Safety and Efficacy of a New
Thrombolytic)-2, GUSTO (Global Use of Strategies to
Open Occluded Coronary Arteries)-III, and COBALT (Con-
tinuous Infusion Versus Double-Bolus Administration of
Alteplase) [1–4]. However, as discussed by several authors
[5–8], there are issues with trials of this type that make
them considerably less credible than superiority trials.
Terminology
‘Noninferiority’ is a relatively new term that has not been
universally adopted, and in the past noninferiority and
equivalence trials, which have an important distinction,
have both been referred to as ‘equivalence trials’. To make
the confusion even worse, both of these terms are some-
what misleading.
It is fundamentally impossible to prove that two treatments
have exactly equivalent effects. Equivalence trials, therefore,
aim to show that the effects differ by no more than a
specific amount. This tolerance is known as the equivalence
margin, and is often denoted by the symbol d. In an
equivalence trial, if the effects of the two treatments differ by
more than the equivalence margin in either direction, then
equivalence does not hold. Noninferiority trials, on the other
hand, aim to show that an experimental treatment is not
worse than an active control by more than the equivalenceCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Snapinn
margin. An improvement of any size fits within the defini-
tion of noninferiority. Bioequivalence trials are true equiva-
lence trials, but it is difficult to imagine any trial comparing
the clinical effects of an experimental treatment and active
control that would not more appropriately be termed a
noninferiority trial.
Assay sensitivity
Probably the greatest difficulty with noninferiority trials
relates to the issue of assay sensitivity, or the ability of a
specific clinical trial to demonstrate a difference between
treatments if such a difference truly exists. A trial that suc-
cessfully demonstrates superiority has simultaneously
demonstrated assay sensitivity. However, a noninferiority
trial that successfully finds the effects of the treatments to
be similar has demonstrated no such thing. A well-exe-
cuted clinical trial that correctly demonstrates the treat-
ments to be similar can not be distinguished, on the basis
of the data alone, from a poorly executed trial that fails to
find a true difference. Therefore, a noninferiority trial must
rely on an assumption of assay sensitivity on the basis of
information external to the trial, such as the quality control
procedures or the reputation of the investigator.
The International Conference on Harmonization guidelines
[9] list a number of factors that can reduce assay sensitiv-
ity. These include poor compliance with the study medica-
tion, poor diagnostic criteria, excessive variability of
measurements, and biased end-point assessment. In order
to be credible, therefore, noninferiority trials must attempt
to avoid these factors to every possible extent, and even
then might not be able to escape suspicion. For example,
a successful superiority trial can be very credible despite a
moderately large rate of discontinuation from study drug,
but a successful noninferiority trial would be less so,
because discontinuations can obscure a true treatment
effect and thus reduce assay sensitivity.
Analysis of noninferiority trials
Intention-to-treat (ITT) is widely recognized as the most
valid analytic approach for superiority trials that involve
long-term end-point follow up, because it adheres to the
randomization procedure and is generally conservative
[10]. Although some might argue that the ITT analysis is
overly conservative, most would agree that a positive ITT
analysis of a superiority trial is convincing.
Unfortunately, no such conservative analysis exists for
noninferiority trials. For example, including data after study
drug discontinuation in the analysis, as ITT does, tends to
bias the results toward equivalence, which could make a
truly inferior treatment appear to be noninferior. The per-
protocol analysis, on the other hand, excludes data from
patients with major protocol violations. However, exclud-
ing these data can substantially bias the results in either
direction. For example, patients in a survival trial might
discontinue study medication due to the development of
heart failure, which is a strong risk factor for mortality.
Therefore, noninferiority trials are often analyzed using ITT
and per-protocol approaches, and only if both approaches
support noninferiority is the trial considered positive. Even
in this case, however, the possibility of bias can not be
ruled out, and it can be awkward to have different analytic
strategies for superiority and noninferiority trials.
Blinding
Blinding is one of the most important bias-avoiding tech-
niques available to clinical trialists. It is not always feasi-
ble to blind the investigator or patient to the treatment
regimen, but blinded end-point determination is nearly
always possible and should be done, particularly when
the end-point has a subjective component. However,
blinding does not protect against bias nearly as well in a
noninferiority trial as it does in a superiority trial. In a
superiority trial, a blinded investigator can not consciously
or subconsciously influence the results to support a pre-
conceived belief in superiority, but in a noninferiority trial
there is no protection against a blinded investigator
biasing the results toward a preconceived belief in equiv-
alence by assigning similar ratings to the treatment
responses of all patients.
Specifying the noninferiority margin
It can be quite difficult to specify an appropriate noninferi-
ority margin. There are two basic approaches, both of
which have serious drawbacks. One approach is to
specify the equivalence margin on the basis of a clinical
notion of a minimally important effect. However, this is
clearly subjective, and it is possible with this approach to
set the equivalence margin to be greater than the effect of
the active control, which could lead to harmful treatments
fitting within the definition of noninferiority.
To avoid this, the equivalence margin is often chosen with
reference to the effect of the active control in historical
placebo-controlled trials. When the equivalence margin is
chosen in this way, there is some basis on which to claim
that a positive noninferiority trial implies that the new treat-
ment is superior to placebo. However, this claim requires
an assumption that the effect of the active control in the
current trial is similar to its effect in the historical trials.
That assumption can be undermined by differences with
respect to design features (eg the patient population,
dosage regimen of the active control, end-point definition
or concomitant therapies), or by an inconsistency in the
effect of the active controls among the historical placebo-
controlled trials (beyond that expected by random
chance). For this reason, the equivalence margin usually
includes some type of buffer. Rather than basing it on the
full predicted effect of the active control, it is often based
on the lower bound of a confidence interval for that effecthttp://cvm.controlled-trials.com/content/1/1/019
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(accounting for within-trial and trial-to-trial variability), or on
preservation of a specific fraction (eg 50%) of the effect of
the active control.
Sample size
Although noninferiority trials typically have smaller sample
sizes than active-controlled superiority trials, they can have
considerably larger sample sizes than placebo-controlled
trials. This is because the equivalence margin is often
much smaller than the treatment difference for which a
placebo-controlled trial is powered. In addition, the sample
size of a noninferiority trial is very sensitive to the assumed
effect of the new treatment relative to the active control;
the sample size can be considerably larger if the two treat-
ments are assumed to be equivalent than if the new treat-
ment is assumed to be slightly more effective than the
active control.
For example, COBALT used a noninferiority margin of
0.4%, and the sample size of 7169 was based on the
assumption that the experimental treatment was superior
to the standard by 0.9% [3]. Had the investigators
assumed that the treatments were equivalent, a sample
size of approximately 50000 would have been required
[4]. By contrast, a placebo-controlled trial intended to
demonstrate a 2.5% reduction (from 10 to 7.5%) with
80% power would require approximately 4000 patients.
Assessing superiority
Both noninferiority and superiority can be assessed in the
same clinical trial without statistical penalty. One conse-
quence of this is that most, if not all, active-controlled clini-
cal trial protocols should define a noninferiority margin and
include a noninferiority hypothesis. If a protocol has a non-
inferiority hypothesis but no superiority hypothesis, it is still
valid to do both tests. However, if a protocol has a superi-
ority hypothesis but no noninferiority hypothesis, adding a
noninferiority hypothesis after the trial is complete would
be problematic because of the subjective component in
the definition of the noninferiority margin.
Conclusion
There are inherent problems with noninferiority trials that
make their results clearly less credible than those of a
placebo-controlled trial. However, it is not always possi-
ble to include a placebo treatment for ethical reasons,
and there will always be a need for clinical trials to test
new treatments that are either no more effective than the
standard (but which may offer some other advantage,
such as better safety or more convenient dosing) or offer
such a small increase in efficacy that the size of a superi-
ority trial would be prohibitive. Trialists will continue to do
noninferiority trials because there is often no alternative.
Anyone performing such a trial or evaluating its results,
however, must be aware of the issues and account for
them appropriately.
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